{ "items": [ "\n\n
\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n5 February 2021
\n \n \n \nA preprint of ongoing work to assess effectiveness of Oxford\u2019s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 \u2018Kent\u2019 coronavirus strain currently circulating in the UK to previously circulating variants.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n4 February 2021
\n \n \n \nThe University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n26 January 2021
\n \n \n \nToday, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n10 December 2020
\n \n \n \nUniversity of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n23 November 2020
\n \n \n \nThe University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n19 November 2020
\n \n \n \nThe ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
\n \n\n \n \n\n \n\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n14 November 2020
\n \n \n \nResearchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n23 September 2020
\n \n \n \nPublic trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.
\n \n\n \n \n\n \n\n \n \n \n \n Parents & Carers\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n18 August 2020
\n \n \n \nIn an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n27 July 2020
\n \n \n \nCongratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!
\n \n\n \n \n\n \n\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n2 July 2020
\n \n \n \nThe European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n26 June 2020
\n \n \n \nThe Duke of Cambridge visits the University of Oxford\u2019s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n15 June 2020
\n \n \n \nAstraZeneca has reached an agreement with Europe\u2019s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford\u2019s COVID-19 vaccine, with deliveries starting by the end of 2020.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n22 May 2020
\n \n \n \nOxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Recruitment\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n24 April 2020
\n \n \n \nUniversity of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n20 April 2020
\n \n \n \nA multi-site project, called \u2018What\u2019s the STORY?\u2019 has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research\u2019s (NIHR) Urgent Public Health Response.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n17 April 2020
\n \n \n \nFive projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n27 March 2020
\n \n \n \nUniversity of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won\u2019t be ready for some weeks still.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n18 March 2020
\n \n \n \nA vaccine candidate for COVID-19 has been identified by researchers from the Oxford Vaccine Group and Oxford's Jenner Institute.
\n \n\n \n \n\n \n\n \n \n \n \n Public Engagement\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n20 January 2020
\n \n \n \nA new exhibition tells the story of Oxford\u2019s role in the fight against typhoid, from pioneering efforts to eliminate typhoid in the era of Lewis Carroll\u2019s Alice in Wonderland to game-changing present-day vaccine trials
\n \n\n \n \n